Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dry eye

National Institute for Health and Care Excellence NICE logo

NICE backs Amicus Therapeutics’ Galafold

Recommends oral alternative for treating Fabry disease

- PMLiVE

Shire wins EU licence for pancreatic cancer drug Onivyde

Combination treatment is the first approved for this patient population

Shire Basingstoke

Shire gives up on Momenta-partnered Humira biosimilar

Will fund programme for another 12 months while divesting ongoing activities to Momenta

Shire Basingstoke

Shire launches dry eye drug Xiidra in US

Sparks rivalry with Allergan’s blockbuster Restasis as first new dry eye treatment in 13 years

- PMLiVE

Rare blood cancer therapy Oncaspar gets NICE green light

Baxalta’s acute lymphoblastic leukaemia treatment recommended for NHS use

- PMLiVE

HIV prevention pill heads July CHMP recommendations

Gilead’s Truvada given positive opinion alongside Ipsen Pharma’s Cabometyx and Eisai’s Kisplyx

Shire Basingstoke

FDA finally approves Shire’s potential blockbuster Xiidra

Dry eye disease treatment wins US licence

Shire Basingstoke

Shire receives FDA nod for self-infusion of Glassia

The company has also struck a deal with Pfizer to expand its GI portfolio

Shire Basingstoke

Shire completes $32bn Baxalta merger

Creates world leading rare diseases specialist

- PMLiVE

Shire launches digital ‘paper planes’ for rare disease campaign

#FlyForMPS allows supporters to track the miles their plane travels

Shire Basingstoke

Shire says Baxalta merger on track despite US tax clampdown

After Pfizer/Allergan deal falls apart company says its combination will still go ahead

Shire Basingstoke

Shire launches long-acting ADHD drug Intuniv in UK

Also plans to launch the once-daily treatment in Japan later this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links